Wanbury Q2 FY25 revenue at Rs. 161.2 crore, up 11.6%
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Subscribe To Our Newsletter & Stay Updated